PF-06372222 and key residues are shown as sticks
The Bottom Line Success on GLP-1 medications isn't just about taking your weekly injectionit's about pairing that medication with a strategic nutrition approach that preserves muscle, minimizes side effects, and sets you up for long-term sustainable weight loss
Tirzepatide is a dual-agonist , meaning it works by targeting two hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Retatrutide is a triple-agonist , meaning it targets three hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Glucagon: affects energy use and fat metabolism Early studies show that retatrutide may be more successful than tirzepatide at managing diabetic kidney disease, as well as for weight control, while tirzepatide may be better at managing blood glucose
Clinical data on tirzepatide in type 2 diabetesthe SURPASS clinical trial program Early clinical studies with tirzepatide revealed a marked and dose-dependent reduction of HbA1c and further glycemic parameters in patients with T2D in various ethnic cohorts (clinical trials registration numbers NCT03322631, NCT03131687, and NCT03311724) (6668)
As neurological and medical complications after stroke are not properly predicted, prevented, or dealt with, they are considered to constitute the main cause of the high morbidity and mortality associated with strokes (78)
SGLT2 inhibitors, but not GLP-1 receptor agonists, reduce incidence of gout in people living with type 2 diabetes across the therapeutic spectrum
